Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas - Seite 2

• 304 convertible bonds issued on March 14, 2023, April 20, 2023, May 22, 2023, June 15, 2023, August 10, 2023, September 15, 2023, October 20, 2023, October 24, 2023, November 15, 2023 and November 15, 2023, January 9, 2024 and February 2, 2024, entitling its holder, Atlas Special Opportunities, LLC, to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds pursuant to the Subscription Agreement entered into between the Company and Atlas Special Opportunities, LLC on March 1, 2023, as amended on September 10, 2023 and December 22, 2023.

 

END

About Oxurion

Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

Please contact for additional information:

Oxurion NV Pascal Ghoson Chief Executive Officer [e-mail]

Backstage Communication Jurgen Vluijmans Partner [e-mail]

---

1 Press release Oxurion, 02/03/2023